Cite
HARVARD Citation
Kantarjian, H. et al. (2018). Patient‐reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 124 (10), pp. 2151-2160. [Online].